Cargando…

Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab

Orbital myositis (OM) is an extremely rare ocular extraintestinal manifestation of inflammatory bowel disease. Acute or chronic inflammation of one or more extraocular muscles leads to symptoms related to the mass effect including orbital pain, swelling, ophthalmoplegia, proptosis, and diplopia. Alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandhu, Sunny, Wang, Timothy, Donet, Jean A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287271/ https://www.ncbi.nlm.nih.gov/pubmed/35919668 http://dx.doi.org/10.14309/crj.0000000000000775

Ejemplares similares

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
por: Yeh, Jennifer E., et al.
Publicado: (2017)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Painless orbital myositis
por: Chakor, Rahul T., et al.
Publicado: (2012)

Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
por: Verma, Sanam, et al.
Publicado: (2013)

Diagnostics and treatment of orbital myositis
por: Pidro, Aida, et al.
Publicado: (2022)

Orbital myositis as an initial manifestation of Behcet's disease
por: Abe, Shinya, et al.
Publicado: (2022)

Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report
por: Yeh, Heng, et al.
Publicado: (2021)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

Prophylactic Treatment with Vedolizumab in the Prevention of Postoperative Recurrence (POR) in High-Risk Crohn’s Patients
por: Frieri, Giuseppe, et al.
Publicado: (2023)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

A Case of Orbital Myositis Presenting With Dizziness
por: Aquilina, Neville, et al.
Publicado: (2018)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Safety of dual biological therapy in Crohn’s disease: a case series of vedolizumab in combination with other biologics
por: Mao, Eric J, et al.
Publicado: (2018)

Case report of metastatic breast cancer mimicking ileal Crohn's disease
por: Maharajh, Sandeep, et al.
Publicado: (2021)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Keep an Eye Out for Crohn’s Disease: Orbital Myositis as the Initial Sign before Gastrointestinal Manifestations
por: Hoilat, Gilles Jadd, et al.
Publicado: (2020)

Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
por: Au, Michael, et al.
Publicado: (2022)

Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn's Disease: A 9-Year Survival
por: Kothadia, Jiten P., et al.
Publicado: (2019)

Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn’s Disease Patient
por: Groudan, Kevin, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Ileal Signet Ring Cell Carcinoma Masked by Crohn Disease
por: Hammami, Muhammad Baraa, et al.
Publicado: (2020)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn’s Disease
por: Busutti, Marco, et al.
Publicado: (2023)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
por: Choi, Sujin, et al.
Publicado: (2021)

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
por: Feagan, Brian G, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Two Cases of Orbital Myositis as a Rare Feature of Lyme Borreliosis
por: Sauer, Arnaud, et al.
Publicado: (2011)

Medical and Surgical Treatment in Pediatric Orbital Myositis Associated with Coxsackie Virus
por: Gil, Pedro, et al.
Publicado: (2015)

Shingles as the underlying cause of orbital myositis in an adolescent: A case report
por: Conrady, Christopher D., et al.
Publicado: (2016)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
por: Yajnik, Vijay, et al.
Publicado: (2017)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Holmer, Ariela K., et al.
Publicado: (2020)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
por: Ayoub, Fares, et al.
Publicado: (2022)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
por: Vadala di Prampero, Salvatore, et al.
Publicado: (2016)

Vedolizumab combined with surgical resection successfully treated perforating Crohn’s disease with peritoneal space to rectal and vaginal fistulas: a case report
por: Chung, Meng-Wu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oc630kuc10aduhjngdribeeo0c